Research Revolutionizing Patient Care and Treatment Strategies

Groundbreaking research illustrates how fit-for-purpose real-world data
can support innovative research and decision-making across the development lifecycle, from early feasibility through post-approval studies.

Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States

Michael Wallington, Yong Chen, Fei Jie, Monica Patterson, Karen Repetny, Michelle Fanale, Simon Purcell, Jacob Ambrose, Christina M. Zettler, Andrew J. Belli, Laura L. Fernandes, Ching-Kun Wang
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematologic malignancy with a defined, first-line (1L) standard of care (SOC). Several novel agents have been approved for the treatment of relapsed/refractory (R/R) disease in recent years, leading to a heterogeneous treatment landscape in later lines of therapy (LOTs). Our study aimed to characterize real-world treatment patterns for patients who received third-line or later (3L+) therapy using a multiple index date qualification methodology to enable a comparison to clinical trials. Methods: This observational, retrospective study identified eligible patients in the COTA (now Verana Health) electronic health record-based, DLBCL dataset. Patients were assessed for eligibility at the initiation of each 3L+ LOT.…

A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data

Alexander Breskin, Mostafa Shokoohi, Beatrice Suero, Di Wang, Paul Spin, Qiufei Ma, Glenn S Kroog, Christian Hampp
Patients with limited life expectancy (LE) are often excluded from oncology trials based on subjective judgment, posing a challenge when contextualizing trial findings with real-world data (RWD). This study evaluated the feasibility of modeling mortality in RWD for relapsed/refractory multiple myeloma (RRMM) to replicate patient exclusion (LE < 6 months) for application in an external control arm study.A targeted literature review (TLR, January 2016-March 2022) was performed to identify mortality prediction models in RRMM. Because no suitable model was found, a de novo mortality model was developed using the COTA database.Twenty-one prognostic factors identified via literature review and clinical experts were included in the models. Cox proportional hazards models with bootstrap validation to correct for optimism were used to identify the best-performing model. A threshold of ≥50% predicted mortality probability within 6 months of the start of the line of therapy (LOT) was used for sensitivity and specificity estimates.Patients (N = 1,112) contributed 2,626 LOTs. A model with the top 20 prognostic factors maximized concordance and accuracy while achieving pre-specified performance thresholds, except for the F1 score. The predicted and observed 6-month mortality probability were both 26%.Mortality prediction for RRMM remains challenging with RWD. The de novo model exhibited strong discrimination performance but low F1 score, suggesting it may be useful to identify patients at highest risk who may be least likely to meet trial LE criteria.

IBCL-1346: Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 vs Real-World Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma

Habte Yimer, Lorenzo Falchi, Rong Tao, Loic Ysebaert, Michal Kwiatek, Abel Costa, Theodoros P Vassilakopoulos, Marcel Nijland, Shane Gangatharan, Dai Maruyama, Abualbishr Alshreef, Anthony Wang, Junhua Yu, David Tybor, Yves Mbous, Kavita Sail, Zhijie Ding, Gauri Sunkersett, JP Mei, Kim Linton

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma

Lorenzo Falchi, Martin Hutchings, David Tybor, Junhua Yu, Abualbishr Alshreef, Anthony Wang, Kavita Sail, Zhijie Ding, Alex Mutebi, Poliana Patah, Nisha Kishore, Ali Rana, Elena Favaro, Kim Linton
Patients with relapsed/refractory follicular lymphoma (R/R FL) often experience multiple disease recurrences with progressively shorter duration of remission. Chemoimmunotherapy (CIT) is commonly used for R/R FL in second-line and later settings but is not curative; novel, improved treatments are needed. Epcoritamab, a CD3 × CD20 bispecific antibody, is approved as monotherapy for R/R FL after ≥ 2 lines of therapy (LOTs) and combined with lenalidomide and rituximab (R2) for R/R FL. Epcoritamab + R2 pivotal data demonstrated superiority over R2, but no comparison of epcoritamab + R2 versus CIT exists. Therefore, we conducted an adjusted comparative analysis of epcoritamab + R2 from arm 2 of the phase 1b/2 EPCORE NHL-2 trial (NCT04663347; n = 111; US, 23.4%) versus R2/CIT using COTA individual patient-level electronic health records (n = 380; US, 100%) of patients with R/R FL after ≥ 1 previous LOT. Epcoritamab + R2 improved response rates over R2/CIT (overall response, 96.9% versus 80.5%, P < .001; complete response, 90.2% versus 55.1%, P < .001). Epcoritamab + R2 improved duration of response (HR, 0.29 [95% CI, 0.18-0.47]; P < .001), duration of complete response (HR, 0.31 [95% CI, 0.17-0.55]; P < .001), progression-free survival (HR, 0.43 [95% CI, 0.28-0.68]; P < .001), and overall survival (HR, 0.33 [95% CI, 0.16-0.70]; P = .003) over R2/CIT. These findings support epcoritamab + R2 as a promising chemotherapy-free treatment option for R/R FL.

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative

Natalie Levy, Paige Sheridan, Ulka Campbell, David Lenis, Inish O'Doherty, Adina Estrin, Nileesa Gautam, Monica Iyer, Sarah McDonald, Andrew Belli, Gillis Carrigan, K Arnold Chan, James Chen, Victoria Chia, Neil Dhopeshwarkar, Joy Eckert, Laura Fernandes, Joel Greshock, Rachele Hendricks-Sturrup, Jenny Huang, XiaoLong Jiao, Sajan Khosla, Orsolya Lunacsek, Lynn McRoy, Yanina Natanzon, Osayi Ovbiosa, Nelson Pace, Simone Pinheiro, Megan Rees, Jennifer Rider, Mothaffar Fahed Rimawi, Travis Robinson, Carla Rodriguez-Watson, Chithra Sangli, Khaled Sarsour, Sebastian Schneeweiss, Mark Shapiro, Mark Stewart, Aliki Taylor, C K Wang, Shirley Wang, Yiduo Zhang, Ann Madsen
The Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative seeks to advance understanding of when real-world data (RWD) can generate valid treatment effectiveness estimates by emulating completed oncology randomized controlled trials (RCTs). A prerequisite for meaningful RCT emulation insights is the identification and use of RWD with sufficient fitness to satisfy RCT-specific data elements. We conducted a systematic, multi-stage feasibility assessment of six commercially available US electronic health record-based RWD sources across 23 candidate oncology RCTs. Each potential RCT-RWD combination was first screened for availability of the RCT indication, outcomes, and sample size ≥ 1.5-times enrollment for each trial arm.…

Variation in metastatic colorectal cancer (mCRC) patient survival among different oncology practice settings with guideline-concordant molecular testing.

Wenners Ballard, Chiranjeev Dash, Connor Shimberg, Jialing Zhu, John L. Marshall
e23082 Background: Molecular testing is paramount for treating patients (pts) with mCRC. Guidelines, including ASCO and NCCN, recommend testing for mismatch repair deficiency (dMMR)/microsatellite instability high (MSI-H), BRAF V600E mutation, RAS mutations, and HER2 amplification, as these molecular subtypes have profound therapeutic implications. This study evaluates molecular testing rates in a real-world cohort of pts with mCRC at an academic center, an academic affiliate site, and a community practice. Methods: In this retrospective study, a cohort of pts was obtained using COTA electronic health record data. The study included adults diagnosed with mCRC between January 1, 2022, and January 1, 2024, at Lombardi Comprehensive Cancer Center (LCCC), Non-Lombardi MedStar settings (NLM), and a nearby community oncology practice (COP).…

Real-world outcomes and subsequent treatment utilization following anti-B-cell maturation antigen antibody-drug conjugate exposure in patients with multiple myeloma.

Meletios A. Dimopoulos, Jorge Monge Urrea, Efstathios Kastritis, Xavier P. Leleu, David S. Siegel, Enrique M. Ocio, Madhu Nagaraj, Rafla Hassan, Sundar Jagannath, Katja C. Weisel, Nicolle Bonar, Mostafa Shokoohi, Christian Hampp, Jeannette Green, Olivier Humblet, Alexander Breskin, Glenn S. Kroog, Qiufei Ma, Shaji Kumar
e19503 Background: The anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) belantamab mafodotin is approved in the USA and EU for relapsed/refractory multiple myeloma (RRMM). Understanding treatment options and patient outcomes following ADC failure is clinically important. This study describes post-ADC treatment patterns and clinical outcomes in real-world patients with RRMM. Methods: Adult patients with MM who received an ADC and initiated ≥1 subsequent line of therapy (LOT) were included. The index date was the start of the first post-ADC LOT. Data were obtained from chart reviews at International Myeloma Foundation International Myeloma Working Group (IMF IMWG) academic sites, and US electronic health records from largely community sites (COTA and Guardian Research Network [GRN]).…

CONTEMPORARY REAL-WORLD TREATMENT PATTERNS, MRD TESTING PATTERNS AND OUTCOMES OF ADULT PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATED IN THE UNITED STATES IN 2018 OR LATER

Olalekan Oluwole, Enrico de Nigris, Jacob Ambrose, Jennifer Prescott, Razia Akhtar, Diana Chirovsky, Holger Keim, Christina Zettler, Laura Fernandes, Ming He
Background: Historically, B-cell ALL in adults has been characterized by poor long-term outcomes, including high relapse rates even among frontline (1L)-treated patients (pts) who achieve complete response (CR). Targeted therapies, such as blinatumomab (blina), inotuzumab (ino) and chimeric antigen receptor T-cell (CAR-T) therapy, have revolutionized the treatment (tx) landscape. There is scant contemporaneous evidence of real-world tx patterns and outcomes among pts treated from the 1L through the relapsed/refractory (R/R) setting, including minimal residual disease (MRD) testing. Aims: To characterize contemporary real-world tx, MRD testing patterns, and outcomes among pts with 1L and R/R B-cell ALL.…

Assessing the Impact of Inclusion of Patients with Missing Eastern Cooperative Oncology Group (ECOG) Performance Status in Real-World Outcomes of Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL)

Michael Wallington, Yong Chen, Fei Jie, Monica Patterson, Karen Repetny, Michelle Fanale, Simon Purcell, Jacob Ambrose, Christina M. Zettler, Andrew J. Belli, Laura L. Fernandes, Ching-Kun Wang
OBJECTIVES: An Eastern Cooperative Oncology Group (ECOG) score of 0-2 is often required for clinical trial enrollment. In real-world data, ECOG status can be missing/unknown (M/U) due to lack of assessment, documentation, or abstraction. This analysis assessed differences in outcomes among patients with ECOG 0-2 versus M/U in a real-world population similar to the ECHELON-3 trial (NCT04404283). METHODS: Using the COTA database, eligible adult patients received at least 2 prior lines of therapy (LOTs). Qualifying index-LOTs (multiple per patient) were identified by initiation of third line or later (3L+) between OCT/18/2017 and DEC/31/2023, no documentation of an ECOG score of ≥3 at baseline, no exclusionary treatment or diagnosis history, and sufficiently precise key dates.…

External Control Arm Feasibility Across External Data Sources in Oncology: Methodological and Regulatory Science Considerations

Bernat Navarro, Kawther Abdilleh, Amy Alabaster, Peter Ansell, Li Chen, Gregory S. Calip, PharmD, Ruthanna Davi, Janet Espirito, Laura L. Fernandes, Sebastian Zavala Hoffmann, Patricia Luhn, Xinran Ma, Patricia Prince, Mark Riffon, Xiang Yin, Mark Stewart, Hillary Andrews, Jeff Allen
OBJECTIVES: External control arms (ECAs) can generate scientifically rigorous comparison data when randomized controls are infeasible, but methodologies for developing ECAs using real-world data (RWD) and historical clinical trials (HCTs) are not universally accepted. As a proof-of-concept, Friends ’ pilot evaluated ECAs from multiple external data sources mirroring the control arm of the metastatic pancreatic RESOLVE HCT. Objectives included: (1) operationalizing target-trial eligibility criteria across heterogeneous RWD sources; (2) characterizing data missingness and quality; and (3) comparing outcomes against the HCT control arm. METHODS: We developed a statistical analysis plan (SAP) to translate target-trial eligibility criteria, propensity score modeling, and variable definitions into standardized operational rules.…

Real-world Treatment Patterns and Outcomes Among Patients with Newly-Diagnosed Acute Myeloid Leukemia in the United States

Elizabeth Dianne Pulte, Laura L Fernandes, Kelly Norsworthy, Joseph Wynne, Eric Hansen, Andrew J Belli, Anna Barcellos, Christina M Zettler, Rebecca Bystrom, Jonathon Vallejo, Catherine Lerro, Ching-Kun Wang, Donna Rivera, Angelo de Claro
PURPOSE: The US Food and Drug Administration has approved multiple new treatments for AML since 2017 based on demonstrated efficacy and safety in clinical trials. However, the uptake of new treatments and effectiveness in the routine clinical practice are largely unknown. METHODS: A retrospective observational study was conducted to examine first-line therapy in patients with AML who were treated at institutions providing data to the COTA database. Information on demographics, disease characteristics, treatments, and outcomes was collected and analyzed descriptively. RESULTS: Among the 2,516 patients eligible for inclusion in our analysis, cytarabine-based intensive chemotherapy (IC w/cytara) was the most commonly used treatment, followed by hypomethylating agents (HMA) with venetoclax (HMA+ven), HMA alone, and investigational treatment. Use of HMA+ven increased over time since its approval in 2018, whereas use of IC w/cytara and HMA alone decreased. Complete remission rates were 45% overall and highest in patients treated with IC w/cytara (61%) or investigational therapy (62%). CONCLUSION: Overall survival was highest for patients treated with IC w/cytara, although differences in baseline patient characteristics make direct comparison infeasible. Uptake of HMA+ven as a first-line treatment for patients with AML has been more rapid compared with other newly approved therapies. Outcomes for patients treated in routine practice were similar to those seen in clinical trials. Further research may be helpful in characterizing real-world effectiveness and safety in specific subpopulations and disease subtypes.